A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

NCT02467361 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: BBI608
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

Sumitomo Pharma America, Inc.